lululab’s LUMINI Receives CES 2019 Innovation Award

lululab, a member company of the K-ICT Born2Global Centre, has received a CES Innovation Award in the “Fitness, Sports, and Biotech” category, ahead of the consumer electronics show CES 2019, to be held in Las Vegas in January.

lululab, a spinoff company of C-Lab—Samsung Electronics’ in-house venture program—developed the AI skincare assistant LUMINI. Based on AI technology, the device scans and analyzes the user’s skin condition in only 10 seconds and recommends the most suitable cosmetic products.

LUMINI quantifies skin condition based on six criteria, including wrinkles, pores, skin trouble, and melasma, which are the most common skin problems, and recommends the best solution. Lumini systematically manages the user’s skin condition based on skin-related data and helps the user use that information to improve his or her skin in the future, explains a media release from K-ICT Born2Global Centre.

“LUMINI is the first AI technology-based beauty solution that allows you to complete a skin test in only 10 seconds by taking photos, without ever touching your skin,” says lululab CEO Yongjoon Choe, in the release. “By collecting big data on skin types related to ethnic origin and environment, we aim to transform LUMINI into an AI solution that recommends customized lifestyles and foods for all kinds of users.”

According to the company, its AI skincare assistant LUMINI is designed to provide customers with a new offline shopping experience that includes everything from AI skin analysis to product recommendation and purchase.

[Source(s): K-ICT Born2Global Centre, PR Newswire]

Penn Medicine Surgeons Perform World’s First Robotic Bilateral Breast Reconstruction

A team of surgeons from the Perelman School of Medicine at the University of Pennsylvania are the first in the world to use a surgical robot to assist with a bilateral free flap breast reconstruction – a procedure in which tissue is taken from the lower abdomen – similar to a “tummy tuck” – and used to rebuild the breast.

The robot allows surgeons to make a much smaller incision into the abdominal wall muscles, allowing patients to recover and be discharged more quickly and without the use of addictive narcotic painkillers.

Suhail Kanchwala, MD, an associate professor of Plastic Surgery, led the team that performed the procedure, which took place at Pennsylvania Hospital earlier this month. Kanchwala partnered with Ian Soriano, MD, FACS, a clinical assistant professor of Surgery, who specializes in minimally invasive procedures, to develop the technique.

For more information, read the full press release at

Gas-Filled Balloon Device Is Safe, Effective for Weight Loss, Per Study

In its first year of commercial use, the swallowable, gas-filled, three-balloon weight loss device (Obalon, Obalon Therapeutics) demonstrated a good safety record and resulted in greater weight loss than seen in the pivotal randomized trial leading to its US approval, new data show.

Safety and efficacy results from more than 1300 patients at over 100 sites in Obalon’s voluntary registry were presented recently at Obesity Week 2018, according to a media release from Medscape.

Approved by the US Food and Drug Administration (FDA) in 2016, the Obalon Balloon System consists of three balloons that are delivered to the stomach via a capsule that the patient swallows. Once in place, the balloons are inflated with attached microcatheters and left in for 6 months, after which they are retrieved endoscopically. The system is indicated for patients with a body mass index (BMI) of 30 to 40 kg/m2 with or without obesity-related comorbidities.

The registry, in which prescribing physicians enter weight loss and safety data, was launched when the Obalon Balloon System became available in January 2017.

The registry included a total of 1343 patients who swallowed one or more of the gas-filled balloons over a years’ time at 108 US centers. Patients were a mean age of 46 years, 79% were women, and 67% were white.

Mean BMI was 35.4 kg/m2, but 17% had BMIs above the indicated range (> 40 kg/m2), and 12.5% had BMIs below the range (25.1 to 29.9 kg/m2).

Most of the patients (88%) had swallowed all three balloons, with median administration times of second and third balloons at 2.6 and 7.4 weeks after the first one.

Another 9% received just two balloons, and 3% had only one. A majority (82%) kept the balloons in for the entire recommended 6 months, the release explains.

Out of a total of 3818 balloons administered in the registry, deflations occurred in just 0.18% and failure to inflate in 0.13%.

There were no deaths or unanticipated adverse device effects. Two (0.14%) serious adverse device effects were reported — a gastric perforation and dehydration requiring hospitalization and balloon removal — neither had permanent sequelae.

The most common adverse events were abdominal pain and nausea, both each in about 5% of patients, vomiting in 2%, and abdominal distension in 1%.

Overall weight loss was 9.6 kg for the 1177 patients who had three balloons, compared with 6.6 kg and 3.1 kg, respectively, for those with two and one balloons. Total body weight loss was 9.6%, 6.9%, and 3.4%, respectively.

Comparing results at 22 weeks for 787 registry patients with those of the pivotal trial involving 174 participants, weight loss was 9.7 kg versus 7.1 kg, and total percent body weight loss was 10.0% vs 7.1%, per the release.

[Source: Medscape Medical News]

Veterans Prefer Telehealth Consults for Plastic Surgery, According to Study

A pilot study led by Yale plastic surgeons shows that multiple visits to treat various skin conditions could be reduced to one by using telemedicine. The study was published recently in Plastic and Reconstructive Surgery Global Open.

According to the research team, the vast majority of the patients in the Connecticut VA system who participated in the study preferred the telemedicine consultation to a traditional face-to-face visit.

Read the full news story at

The Fascinating Way Actors Coordinate Botox Appointments While Filming Movies

Botox in Hollywood is sort of like an all-black wardrobe in New York City: normal by way of sheer volume, and therefore completely unavoidable. Still, now more than ever, people across the country are seeking authenticity — in beauty ads, on social media, and on the big screen — which, for working actors, presents a dilemma.

How can someone with a smooth (read: Botoxed) forehead also make their surprise-face or ugly-cry look believable on TV or a movie? Turns out, the answer all comes down to timing, puppeteered by the actor, a dermatologist, and the film crew.

From Burned Noses to Ruptured Breasts — the Botched Doctors Share the Craziest New Stories

Just when you think Botched can’t get any more wild, the doctors turn it up a notch.

Ahead of the show’s season five premiere, doctors Terry Dubrow and Paul Nassif shared a few of the craziest surgeries viewers can expect to see.

“I kid you not, this season is really different, for two reasons,” Dubrow tells PEOPLE.

Combining Three Treatment Strategies May Significantly Improve Melanoma Treatment

A study by a team led by a Massachusetts General Hospital (MGH) investigators finds evidence that combining three advanced treatment strategies for malignant melanoma – molecular targeted therapy, immune checkpoint blockade, and the use of tumor-targeting viruses – may markedly improve outcomes. Their report of experiments in cellular and animal models is being published in Science Translational Medicine.

“We found that use of the oncolytic virus T-VEC significantly enhanced therapeutic response and tumor cell killing when combined with a MEK inhibitor and that adding a PD-1 blocker to that regimen further improved therapeutic responses,” says Howard Kaufman, MD, of the MGH Division of Surgical Oncology, senior author of the report. “All three agents we used are already FDA approved, so our study provides justification for using them in combination. A clinical trial to examine this three-drug regimen should be a priority.”

Read the full press release at

Functional Nasal Surgery Relieves Chronic Headache for Some Patients

Nasal surgery to relieve obstructed breathing can reduce or eliminate chronic headaches in selected patients, reports a paper in the December issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Eighty-five percent of patients undergoing functional nasal surgery had at least partial improvement in their headaches, according to a research summary and update by Ahmed M. Afifi, MD, and colleagues of University of Wisconsin, Madison. They write, “These results suggest that the use of nasal surgery to improve headache symptoms is a viable treatment option in appropriately selected chronic headache patients.”

Read the full press release at